Leukocytoclastic vasculitis associated with capecitabine
Journal of Oncology Pharmacy Practice, cilt.30, sa.7, ss.1282-1286, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 7
- Basım Tarihi: 2024
- Doi Numarası: 10.1177/10781552231167812
- Dergi Adı: Journal of Oncology Pharmacy Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1282-1286
- Anahtar Kelimeler: Capecitabine, adverse effect, leukocytoclastic vasculitis, drug-induced vasculitis, colorectal cancer
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC). Case report: A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment. Management and outcome: Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine. Discussion: We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.